Cargando…
What Are the Incentives for Medicare Prescription Drug Plans to Consider Long-Term Outcomes and Cost?
BACKGROUND: Medicare Prescription Drug Plans (PDPs) do not have incentives to consider long-term outcomes and costs associated with both medical and pharmacy benefits (LTOCMP) when making formulary decisions. OBJECTIVE: To identify existing quality measures, payment models, and public reporting tool...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Academy of Managed Care Pharmacy
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10398251/ https://www.ncbi.nlm.nih.gov/pubmed/27348277 http://dx.doi.org/10.18553/jmcp.2016.22.7.773 |
_version_ | 1785084026087800832 |
---|---|
author | Hung, Anna Perfetto, Eleanor M. |
author_facet | Hung, Anna Perfetto, Eleanor M. |
author_sort | Hung, Anna |
collection | PubMed |
description | BACKGROUND: Medicare Prescription Drug Plans (PDPs) do not have incentives to consider long-term outcomes and costs associated with both medical and pharmacy benefits (LTOCMP) when making formulary decisions. OBJECTIVE: To identify existing quality measures, payment models, and public reporting tools for PDPs that are related to formulary decision making and that could be used as potential incentives for PDPs to consider LTOCMP. METHODS: PubMed, Google, and quality measure databases, as well as Center for Medicare and Medicaid Innovation and Centers for Medicare & Medicaid Services (CMS) websites, were searched for appropriate quality measures, payment models, and public reporting tools. RESULTS: Few quality measures and other mechanisms exist that are related to formulary decision making and have the potential to be incentives for PDPs to consider LTOCMP. Only 3 such tools were identified: (1) Medicare Part D star ratings quality measures in use by CMS, (2) the Medicare Plan Finder website, and (3) URAC PBM Accreditation standards and measures. Furthermore, the majority of the quality initiatives identified were only indirectly related to motivating PDPs to consider LTOCMP. CONCLUSIONS: Efforts are needed to develop mechanisms to align PDP incentives with LTOCMP. |
format | Online Article Text |
id | pubmed-10398251 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Academy of Managed Care Pharmacy |
record_format | MEDLINE/PubMed |
spelling | pubmed-103982512023-08-04 What Are the Incentives for Medicare Prescription Drug Plans to Consider Long-Term Outcomes and Cost? Hung, Anna Perfetto, Eleanor M. J Manag Care Spec Pharm Subject Review BACKGROUND: Medicare Prescription Drug Plans (PDPs) do not have incentives to consider long-term outcomes and costs associated with both medical and pharmacy benefits (LTOCMP) when making formulary decisions. OBJECTIVE: To identify existing quality measures, payment models, and public reporting tools for PDPs that are related to formulary decision making and that could be used as potential incentives for PDPs to consider LTOCMP. METHODS: PubMed, Google, and quality measure databases, as well as Center for Medicare and Medicaid Innovation and Centers for Medicare & Medicaid Services (CMS) websites, were searched for appropriate quality measures, payment models, and public reporting tools. RESULTS: Few quality measures and other mechanisms exist that are related to formulary decision making and have the potential to be incentives for PDPs to consider LTOCMP. Only 3 such tools were identified: (1) Medicare Part D star ratings quality measures in use by CMS, (2) the Medicare Plan Finder website, and (3) URAC PBM Accreditation standards and measures. Furthermore, the majority of the quality initiatives identified were only indirectly related to motivating PDPs to consider LTOCMP. CONCLUSIONS: Efforts are needed to develop mechanisms to align PDP incentives with LTOCMP. Academy of Managed Care Pharmacy 2016-07 /pmc/articles/PMC10398251/ /pubmed/27348277 http://dx.doi.org/10.18553/jmcp.2016.22.7.773 Text en © 2016, Academy of Managed Care Pharmacy. All rights reserved. https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits unrestricted use and redistribution provided that the original author and source are credited. |
spellingShingle | Subject Review Hung, Anna Perfetto, Eleanor M. What Are the Incentives for Medicare Prescription Drug Plans to Consider Long-Term Outcomes and Cost? |
title | What Are the Incentives for Medicare Prescription Drug Plans to Consider Long-Term Outcomes and Cost? |
title_full | What Are the Incentives for Medicare Prescription Drug Plans to Consider Long-Term Outcomes and Cost? |
title_fullStr | What Are the Incentives for Medicare Prescription Drug Plans to Consider Long-Term Outcomes and Cost? |
title_full_unstemmed | What Are the Incentives for Medicare Prescription Drug Plans to Consider Long-Term Outcomes and Cost? |
title_short | What Are the Incentives for Medicare Prescription Drug Plans to Consider Long-Term Outcomes and Cost? |
title_sort | what are the incentives for medicare prescription drug plans to consider long-term outcomes and cost? |
topic | Subject Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10398251/ https://www.ncbi.nlm.nih.gov/pubmed/27348277 http://dx.doi.org/10.18553/jmcp.2016.22.7.773 |
work_keys_str_mv | AT hunganna whataretheincentivesformedicareprescriptiondrugplanstoconsiderlongtermoutcomesandcost AT perfettoeleanorm whataretheincentivesformedicareprescriptiondrugplanstoconsiderlongtermoutcomesandcost |